Author Archives: Steve Bryson PhD

FDA Accepts Priority Review Request for Tyvaso DPI

The U.S. Food and Drug Administration (FDA) has accepted United Therapeutics’ application for a priority review of Tyvaso DPI, an experimental dry powder inhaled formulation of treprostinil, to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). …

Microgel-coated Cells Reverse Established PF in Mice

Scientists found that mesenchymal stromal cells (MSCs) — cells that have similar properties to stem cells — individually coated with a soft microgel were able to reverse established lung tissue scarring in a mouse model of pulmonary fibrosis.  Their findings were reported in…

Smoking, Oxygen Use Linked to Higher Hospitalization Risk in IPF

While receiving treatment at specialized centers lowers the risk of hospitalization among patients with idiopathic pulmonary fibrosis (IPF), being a former smoker and requiring oxygen therapy are both associated with a higher likelihood of hospitalization. These are some of the findings of multiple studies that Boehringer Ingelheim will…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums